Ventricular Tachycardia Ablation in LVAD Patients (CHANNELED)
Characterization of Ventricular Tachycardia Ablation in End-stage Heart Failure Patients With Left Ventricular Assist Device
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jakob Lüker, MD
- Phone Number: +49 221 478 82851
- Email: jakob.lueker@uk-koeln.de
Study Contact Backup
- Name: Jan-Hendrik van den Bruck, MD
- Phone Number: +49 221 478 84895
- Email: jan-hendrik.van-den-bruck@uk-koeln.de
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients with end-stage heart failure with an LVAD implanted undergoing VT ablation
Exclusion Criteria:
- Patients <18 years, pregnant women, patients undergoing VT ablation without an LVAD
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
LVAD patients
Patients with end-stage heart failure with an LVAD implanted undergoing VT ablation.
|
VT ablation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mechanism of ventricular tachycardia in LVAD patients (descriptive name of scale)
Time Frame: 12 month
|
Assessment of the mechanism of VT in LVAD patients (e.g LVAD cannula related vs. related to substrate of underlying heart disease)
|
12 month
|
|
Number of patients with ventricular tachycardia recurrence in device interrogation (physiological parameter)
Time Frame: 12 month
|
Assessment of VT recurrence after ablation: Device interrogation and readout of ICD Holter
|
12 month
|
|
Mortality (physiological parameter)
Time Frame: 12 month
|
Assessment of mortality after VT ablation.
|
12 month
|
|
Heart failure Hospitalization (physiological parameter)
Time Frame: 12 month
|
Assessment of Hospitalization for worsening of Heart Failure after VT ablation.
|
12 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Procedure duration (From groin puncture to sheath removal in minutes)
Time Frame: 12 month
|
Evaluation of the duration of VT ablation procedures in LVAD patients
|
12 month
|
|
Fluoroscopy time (minutes)
Time Frame: 12 month
|
Evaluation of the fluroscopy use (in minutes)
|
12 month
|
|
Radiofrequency energy used for ablation (in watts; e.g. 40 Watts)
Time Frame: 12 month
|
Evaluation of the maximum RF-energy used for ablation
|
12 month
|
|
Number of patients suffering from intraprocedural complication (physiological parameter, e.g. hematoma)
Time Frame: 12 month
|
Evaluation of intraprocedural complications of VT ablation
|
12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jakob Lüker, MD, Heart Center University of Cologne
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHANNELED-Registry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.